STENTYS Announces CE Marking of its longest Xposition stent

Portfolio expansion with the addition of a 37 mm stent designed for long coronary lesions

PRINCETON, N.J. and PARIS., STENTYS, a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that it has received CE Marking for the longest version of its Xposition S Sirolimuseluting self-apposing stent.

The Xposition stent portfolio already included three lengths (17 mm, 22 mm and 27 mm), and this 37 mm drugeluting stent is particularly well-suited to the treatment of lesions in the left main coronary artery and in tapered vessels. Segments longer than 25 mm have been demonstrated to have a higher degree of tapering (diameter difference of 0.5 mm or more) and to be an independent predictor of acute stent malapposition with conventional stents1 . Cardiologists now only need to implant a single self-apposing stent rather than a long conventional stent, thus minimizing the risk of malapposition and related complications.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, comments: “We are very pleased to be able to offer cardiologists this new Self-Apposing drug eluting stent that is expected to increase our market share in the hospitals where we market our products.”

Source: STENTYS